Kiniksa Pharmaceuticals International, plc
KNSA
Rang în acțiuni
#2965
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Preț acțiune
$80.80
Capitalizare de piață
$6.30B
Schimbare (1 zi)
1.66%
Schimbare (1 an)
107.23%
Țară
GB
Tranzacționează Kiniksa Pharmaceuticals International, plc (KNSA)
Categorie
Healthcare
Raport P/S pentru Kiniksa Pharmaceuticals International, plc (KNSA)
Raport P/S la data de October 2026 TTM: 7.32
Conform celor mai recente rapoarte financiare și prețului acțiunilor Kiniksa Pharmaceuticals International, plc, raportul P/S actual (TTM) este 7.32. La sfârșitul anului 2023, compania avea un P/S de 4.55.
Istoricul raportului P/S pentru Kiniksa Pharmaceuticals International, plc din 2016 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 7.32 | 119.03% |
| 2024 | 3.34 | -26.59% |
| 2023 | 4.55 | -3.68% |
| 2022 | 4.72 | -77.46% |
| 2021 | 20.94 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.31 | 40.94% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 106.72% |
US
|
